These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 10672267)

  • 1. Neuronal RNA oxidation in Alzheimer's disease and Down's syndrome.
    Nunomura A; Perry G; Hirai K; Aliev G; Takeda A; Chiba S; Smith MA
    Ann N Y Acad Sci; 1999; 893():362-4. PubMed ID: 10672267
    [No Abstract]   [Full Text] [Related]  

  • 2. Age-related distribution of neuropathologic changes in the cerebral cortex of patients with Down's syndrome. Quantitative regional analysis and comparison with Alzheimer's disease.
    Hof PR; Bouras C; Perl DP; Sparks DL; Mehta N; Morrison JH
    Arch Neurol; 1995 Apr; 52(4):379-91. PubMed ID: 7710374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuronal localization of C1q in preclinical Alzheimer's disease.
    Fonseca MI; Kawas CH; Troncoso JC; Tenner AJ
    Neurobiol Dis; 2004 Feb; 15(1):40-6. PubMed ID: 14751769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered metabolism of the amyloid beta precursor protein is associated with mitochondrial dysfunction in Down's syndrome.
    Busciglio J; Pelsman A; Wong C; Pigino G; Yuan M; Mori H; Yankner BA
    Neuron; 2002 Feb; 33(5):677-88. PubMed ID: 11879646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraneuronal abeta-amyloid precedes development of amyloid plaques in Down syndrome.
    Gyure KA; Durham R; Stewart WF; Smialek JE; Troncoso JC
    Arch Pathol Lab Med; 2001 Apr; 125(4):489-92. PubMed ID: 11260621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early accumulation of heparan sulfate in neurons and in the beta-amyloid protein-containing lesions of Alzheimer's disease and Down's syndrome.
    Snow AD; Mar H; Nochlin D; Sekiguchi RT; Kimata K; Koike Y; Wight TN
    Am J Pathol; 1990 Nov; 137(5):1253-70. PubMed ID: 2146882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Life-long overexpression of S100beta in Down's syndrome: implications for Alzheimer pathogenesis.
    Griffin WS; Sheng JG; McKenzie JE; Royston MC; Gentleman SM; Brumback RA; Cork LC; Del Bigio MR; Roberts GW; Mrak RE
    Neurobiol Aging; 1998; 19(5):401-5. PubMed ID: 9880042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebral amyloidosis, ageing and Alzheimer's disease; a contribution from studies on Down's syndrome.
    Mann DM
    Neurobiol Aging; 1989; 10(5):397-9; discussion 412-4. PubMed ID: 2530459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transforming growth factor-beta 1 is in plaques in Alzheimer and Down pathologies.
    van der Wal EA; Gómez-Pinilla F; Cotman CW
    Neuroreport; 1993 Jan; 4(1):69-72. PubMed ID: 8453039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ultrastructure of amyloid fibrils in Alzheimer's disease and Down's syndrome.
    Miyakawa T; Watanabe K; Katsuragi S
    Virchows Arch B Cell Pathol Incl Mol Pathol; 1986; 52(2):99-106. PubMed ID: 2878535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. On the occurrence of neuronal sprouting in the frontal cortex of a patient with Down's syndrome.
    Ohara S; Tsukada M; Ikeda S
    Acta Neuropathol; 1999 Jan; 97(1):85-90. PubMed ID: 9930899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is the "preamyloid" of diffuse plaques in Alzheimer's disease really nonfibrillar?
    Davies CA; Mann DM
    Am J Pathol; 1993 Dec; 143(6):1594-605. PubMed ID: 8256851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developmental Expression and Dysregulation of miR-146a and miR-155 in Down's Syndrome and Mouse Models of Down's Syndrome and Alzheimer's Disease.
    Arena A; Iyer AM; Milenkovic I; Kovacs GG; Ferrer I; Perluigi M; Aronica E
    Curr Alzheimer Res; 2017; 14(12):1305-1317. PubMed ID: 28720071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Up-regulation of E2F-1 in Down's syndrome brain exhibiting neuropathological features of Alzheimer-type dementia.
    Motonaga K; Itoh M; Hirayama A; Hirano S; Becker LE; Goto Y; Takashima S
    Brain Res; 2001 Jun; 905(1-2):250-3. PubMed ID: 11423103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A quartet of Down's syndrome, Alzheimer's disease, cerebral amyloid angiopathy, and cerebral haemorrhage: interacting genetic risk factors.
    McCarron MO; Nicoll JA; Graham DI
    J Neurol Neurosurg Psychiatry; 1998 Sep; 65(3):405-6. PubMed ID: 9728967
    [No Abstract]   [Full Text] [Related]  

  • 16. Alzheimer's disease and Down's syndrome.
    Mann DM
    Histopathology; 1988 Aug; 13(2):125-37. PubMed ID: 2971602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of beta-amyloid deposition in the medial temporal lobe in sporadic Alzheimer's disease, Down's syndrome and normal elderly brains.
    Armstrong RA; Cairns NJ; Myers D; Smith CU; Lantos PL; Rossor MN
    Neurodegeneration; 1996 Mar; 5(1):35-41. PubMed ID: 8731380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alzheimer's disease and Down's syndrome.
    Price DL; Whitehouse PJ; Struble RG; Coyle JT; Clark AW; Delong MR; Cork LC; Hedreen JC
    Ann N Y Acad Sci; 1982; 396():145-64. PubMed ID: 6217772
    [No Abstract]   [Full Text] [Related]  

  • 19. Age-related cortical grey matter reductions in non-demented Down's syndrome adults determined by MRI with voxel-based morphometry.
    Teipel SJ; Alexander GE; Schapiro MB; Möller HJ; Rapoport SI; Hampel H
    Brain; 2004 Apr; 127(Pt 4):811-24. PubMed ID: 14985261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of calcipressin1, an inhibitor of the phosphatase calcineurin, is altered with aging and Alzheimer's disease.
    Cook CN; Hejna MJ; Magnuson DJ; Lee JM
    J Alzheimers Dis; 2005 Sep; 8(1):63-73. PubMed ID: 16155351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.